U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250802) titled 'A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis' on Nov. 18.
Brief Summary: The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.
The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children.
At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib.
Par...